Randomized, Double-Blind, Placebo-Controlled Phase 1 Study to Evaluate Safety, Tolerability, PK/PD of SAD, MAD and Food Effect of Leucettinib-21 in Healthy Male Subjects, and Single Dose in Subjects With Down Syndrome or Alzheimer's Disease
Latest Information Update: 05 Jun 2025
At a glance
- Drugs Leucettinib 21 (Primary)
- Indications Alzheimer's disease; Down syndrome
- Focus Adverse reactions; First in man; Pharmacokinetics
- Acronyms LEUCETTA
- Sponsors Perha Pharmaceuticals
Most Recent Events
- 31 May 2025 Planned End Date changed from 1 Aug 2024 to 1 Jul 2025.
- 31 May 2025 Planned primary completion date changed from 1 Aug 2024 to 1 Jul 2025.
- 19 Feb 2024 Status changed from not yet recruiting to recruiting.